ArticleNorthern clinics of Istanbul2025
Sarcopenia in patients with multiple myeloma and autologous hematopoietic stem cell transplantation.
Article in Northern clinics of Istanbul, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSarcopenia is defined as an age-related loss of muscle quantity as well as quality. Also, it is associated with morbidity and mortality. Multiple myeloma (MM) has a unique aspect with its bone involvement. We aimed to investigate the effect of hematopoietic stem cell transplantation on sarcopenia in MM patients using both CT and metabolic compartment of F-18 FDG PET/CT.
methodsPatients with MM who received first-line treatment and were eligible for autologous stem cell transplantation (ASCT) were included. FDG PET images before transplantation and after 120 days of ASCT were recorded.
resultsWhen were grouped as below and above 60 years of age, a decrease in muscle mass after treatment was observed in both groups (p<0.001). For patients older than 60 years, age was observed to have a significant effect on muscle mass, independent of the treatment (p=0.001). Regarding metabolic assessment of muscles with PET imaging, the lumbar region was observed to be affected by treatment for both age groups (p<0.001). Metabolic volume measurement of the femoral region did not show such difference related to treatment or age.
conclusionWe observed a loss in muscle mass in patients with MM related with treatment. Since PET / CT imaging is routinely used to evaluate disease, it may also be used for the evaluation of muscle as quantity as quality. Awareness of sarcopenia should be increased in patients with MM and caregivers and be supported by physiotherapists to preserve and even to increase muscle mass and strength.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.